Industry Insights

  1. Early Phase Clinical Trial Enrollment: How To Avoid Delays From The Start 1/22/2026

    By operationalizing the early-phase strategies discussed in this article, trial teams can ensure that foundational safety and efficacy data are captured without the delays that derail studies.

  2. Navigating Late-Phase Clinical Trial Enrollment: Strategies To Stay On Schedule 1/22/2026

    Late-phase trial delays cause massive revenue loss. This piece outlines AI pre-screening, direct-to-patient scaling, and retention tactics to hit study goals on time and ensure market readiness.

  3. Integrating The Patient Pathway For Clinical Success 1/22/2026

    Explore how a unified workflow—integrating clinical fit validation with formal trial entry—minimizes friction and reduces the industry’s staggering 60–80% screen failure rates.

  4. We Made Five Predictions For Clinical Research Last Year. Here's What Happened 1/22/2026

    Review 2025’s gap between AI discovery and trial execution, highlighting legislative and FDA shifts to help sponsors operationalize participant experience for 2026.

  5. The "One-Trial" Trap: Why 2026's FDA Efficiency Push Actually Doubles Your Operational Risk 1/22/2026

    When it comes to the FDA's new "one-trial" shift, researcher Johnathon Anderson, Ph.D., warns: Do not confuse efficiency with leniency. Here, Anderson offers three factors to consider when adapting to new FDA trial expectations.

  6. Common Issues And Trends In Clinical Research Vendor Qualification 1/21/2026

    Discover the biggest challenges in vendor qualification, including this one misalignment that affected more than half of surveyed respondents.

  7. "Study Within A Study" Reveals Best Recruitment Strategies For Alzheimer's Trials 1/20/2026

    In this Q&A, Acumen Pharmaceuticals shares findings from its Alzheimer's recruitment study, highlighting what efforts proved the most fruitful.

  8. Endpoints, Procedures, And Deviations Are On The Rise — Why? 1/20/2026

    SCRS Chief Site Success Officer Jimmy Bechtel, MBA, and Tufts CSDD Executive Director Ken Getz, MBA, discuss why they're on the rise explore ways to address, and even accept, them. 

  9. Navigating FDA's New AI Systems: Practical Tips For Regulatory Success 1/19/2026

    AI-assisted reviews are changing FDA submissions. In part two of this series, discover how sponsors can address and even preempt regulatory and legal concerns.

  10. AI At The FDA: Legal Implications And Strategic Considerations For Drug Developers 1/19/2026

    AI-assisted reviews are changing FDA submissions. In part one of this two-part series, familiarize yourself with the FDA's use of AI and key legal concerns it raises.